Ocumetics Technology Corp. provides update on preclinical studies

Abbotsford, British Columbia – Direct News – Ocumetics Technology Corp.

Ocumetics Technology Corp.

Ocumetics Technology Corp.

Calgary, Alberta – TheNewswire – Jan 10, 2022 – Ocumetics Technology Corp. (“Ocumetics”) (TSXV: OTC) is pleased to announce an update on the status of preclinical studies for its first product, the Bionic Lens.

The preclinical studies for the Bionic Lens, consisting of the lens holder and the lens itself, began on October 22, 2021. The preclinical studies are planned in three stages:




Expected completion


Test the Bionic lens holder for structural integrity and ease of insertion by the surgeon.

Start on 22./21. October. Analysis completed in October 2021.

Study on October 21 closed.

Design improvements completed on December 21st.


Test the Bionic Lens Holder with a standard lens used in a typical cataract procedure.

Planned start on February 25, 2022.

Research report expected June 22nd / 22nd


Test the Bionic Lens Holder and the Bionic Lens Optical Element together.

Planned start on March 25, 2022.

Research report expected June 22nd / 22nd

“Our research team has planned three phases of preclinical studies to test the two components of Bionic Lens technology – the retainer and the optical element,” said Dr. Mark Lee, President and CEO of Ocumetics. “Each of these components is considered to be an independent medical product that is tested separately in order to meet the regulatory requirements.”

“We are very satisfied with the findings from the first phase of our preclinical studies,” adds Dr. Lee added. “We obtained invaluable data from our Phase 1 work that we used to refine the design of Bionic Lens technology to 1) improve the function of the lens in the eye, and 2) improve the Bionic Lens surgical procedure to rationalize. “

Successful preclinical studies are followed by clinical phase 1 studies in humans, starting with a planned proof-of-concept study in autumn 2022.

About Ocumetics

Ocumetics Technology Corp. (TSXV: “OTC”) is a Canadian research and product development company specializing in adaptive lens designs. Ocumetics is in the preclinical study phase of a breakthrough technology for ophthalmology – the Bionic Lens. The Bionic Lens is an expandable intraocular lens that fits into the natural lens chamber of the eye and potentially eliminates the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from far to near.


Dr. Mark Lee

President and CEO

(604) 832-6052

Neither the TSX Venture Exchange nor its regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

CAUTIONARY NOTE ON FORWARD-LOOKING INFORMATION: This press release contains certain “forward-looking statements” under applicable Canadian securities laws. Forward-looking statements include, among other things, statements regarding the beginning, timing, and scope of the clinical study program described above and that it will be carried out as expected. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while believed reasonable, are subject to known and unknown risks, uncertainties and other factors that could cause actual results and future events to differ materially from those expressed or implied through such forward-looking statements. These factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to finance, and other considerations that are believed appropriate in the circumstances. There can be no assurance that these statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. The company disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information, future events or for any other reason, except as required by law.

View source version on